Immunocore saw 70% of first-line patients alive at two years. Can two T-cell engagers really beat KIMMTRAK alone?
Immunocore reported 70% two-year survival with KIMMTRAK plus brenetafusp, but a randomised Phase 2/3 trial must confirm the signal.
Features & Analysis